GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.

Eloïne BestionZuzana Macek JilkovaJean-Louis MègeMarie NovelloKeerthi KurmaSeyedeh Tayebeh Ahmad PourGilles LalmanachLise VanderlyndenLionel FizanneFiras BassissiMadani RachidJennifer TraczJérôme BoursierJérôme CourcambeckCindy SerdjebiChristelle AnsaldiThomas DecaensPhilippe HalfonSonia Brun

Published in: Therapeutic advances in chronic disease (2020)

GNS561 is a new potent lysosomotropic compound that could represent a valid medicinal option for hepatic fibrosis treatment through both its anti-fibrotic and its pro-fibrolytic effects. In addition, this study provides a rationale for targeting lysosomes as a promising therapeutic strategy in liver fibrosis.

Keyphrases

liver fibrosis
anti inflammatory
systemic sclerosis
idiopathic pulmonary fibrosis
cancer therapy
signaling pathway
smoking cessation
replacement therapy